Cargando…

Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives

INTRODUCTION: The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report des...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Angela, Veira, Chantal, Malvolti, Stefano, Cherian, Thomas, MacDonald, Noni, Steffen, Christoph, Jones, Ian, Hinman, Alan, Mantel, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342011/
https://www.ncbi.nlm.nih.gov/pubmed/32505440
http://dx.doi.org/10.1016/j.vaccine.2020.05.048
_version_ 1783555343404498944
author Hwang, Angela
Veira, Chantal
Malvolti, Stefano
Cherian, Thomas
MacDonald, Noni
Steffen, Christoph
Jones, Ian
Hinman, Alan
Mantel, Carsten
author_facet Hwang, Angela
Veira, Chantal
Malvolti, Stefano
Cherian, Thomas
MacDonald, Noni
Steffen, Christoph
Jones, Ian
Hinman, Alan
Mantel, Carsten
author_sort Hwang, Angela
collection PubMed
description INTRODUCTION: The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surveys and interviews relating to GVAP, conducted to inform the immunization strategy for the next decade. METHODS: Three surveys and two sets of semi-structured interviews were conducted from 2017 to 2019. Respondents consisted of immunization stakeholders at global, regional, and country levels, and included individuals who had been involved in the development and implementation of GVAP or its monitoring, evaluation and accountability (M&E/A) process; national immunization managers; academics; and personnel from non-governmental organizations and civil society organizations. RESULTS: The surveys and interviews gave consistent results. They highlighted the value of GVAP in increasing visibility for immunization and the benefits of the GVAP M&E/A framework. The main limitations of GVAP were identified as the limited ownership by countries and other stakeholders leading to incomplete implementation of the strategy and poor accountability for achieving GVAP targets. DISCUSSION: These results informed the review of GVAP and the development of its successor strategy, the Immunization Agenda 2030. In addition, these surveys and interviews identified two challenges in assessing the value of GVAP: the need to rely exclusively on stakeholder perspectives and difficulties in attributing benefits. These challenges are inherent in evaluating an over-arching strategy such as GVAP and should be factored into interpretation of the results.
format Online
Article
Text
id pubmed-7342011
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-73420112020-07-14 Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives Hwang, Angela Veira, Chantal Malvolti, Stefano Cherian, Thomas MacDonald, Noni Steffen, Christoph Jones, Ian Hinman, Alan Mantel, Carsten Vaccine Article INTRODUCTION: The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surveys and interviews relating to GVAP, conducted to inform the immunization strategy for the next decade. METHODS: Three surveys and two sets of semi-structured interviews were conducted from 2017 to 2019. Respondents consisted of immunization stakeholders at global, regional, and country levels, and included individuals who had been involved in the development and implementation of GVAP or its monitoring, evaluation and accountability (M&E/A) process; national immunization managers; academics; and personnel from non-governmental organizations and civil society organizations. RESULTS: The surveys and interviews gave consistent results. They highlighted the value of GVAP in increasing visibility for immunization and the benefits of the GVAP M&E/A framework. The main limitations of GVAP were identified as the limited ownership by countries and other stakeholders leading to incomplete implementation of the strategy and poor accountability for achieving GVAP targets. DISCUSSION: These results informed the review of GVAP and the development of its successor strategy, the Immunization Agenda 2030. In addition, these surveys and interviews identified two challenges in assessing the value of GVAP: the need to rely exclusively on stakeholder perspectives and difficulties in attributing benefits. These challenges are inherent in evaluating an over-arching strategy such as GVAP and should be factored into interpretation of the results. Elsevier Science 2020-07-14 /pmc/articles/PMC7342011/ /pubmed/32505440 http://dx.doi.org/10.1016/j.vaccine.2020.05.048 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hwang, Angela
Veira, Chantal
Malvolti, Stefano
Cherian, Thomas
MacDonald, Noni
Steffen, Christoph
Jones, Ian
Hinman, Alan
Mantel, Carsten
Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title_full Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title_fullStr Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title_full_unstemmed Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title_short Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
title_sort global vaccine action plan lessons learned ii: stakeholder perspectives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342011/
https://www.ncbi.nlm.nih.gov/pubmed/32505440
http://dx.doi.org/10.1016/j.vaccine.2020.05.048
work_keys_str_mv AT hwangangela globalvaccineactionplanlessonslearnediistakeholderperspectives
AT veirachantal globalvaccineactionplanlessonslearnediistakeholderperspectives
AT malvoltistefano globalvaccineactionplanlessonslearnediistakeholderperspectives
AT cherianthomas globalvaccineactionplanlessonslearnediistakeholderperspectives
AT macdonaldnoni globalvaccineactionplanlessonslearnediistakeholderperspectives
AT steffenchristoph globalvaccineactionplanlessonslearnediistakeholderperspectives
AT jonesian globalvaccineactionplanlessonslearnediistakeholderperspectives
AT hinmanalan globalvaccineactionplanlessonslearnediistakeholderperspectives
AT mantelcarsten globalvaccineactionplanlessonslearnediistakeholderperspectives